Rollins closed at $47.77, while a valuation narrative from Esteban put fair value at $19.63 and called the stock overvalued. That leaves the pest and termite control company trading at more than twice the estimate, a gap investors could not miss.
The timing matters because the stock has been sliding into the viewfinder. Rollins was down 9.7% over 30 days and 19.1% year to date, even after a 0.5% one-day gain and a 4.3% rise over seven days. Over longer horizons, the picture has been mixed: the shares have delivered a 53.7% total return over five years, but they are still down 15.1% over one year.
Esteban’s framework rested on a business that has kept producing. Rollins reported revenue of US$3.8b and net income of US$529.3m, while generating FCF of $678M on $3.76B of revenue in FY2025. The narrative also pointed to 24 consecutive years of revenue growth, 12 straight years of ROIC of 23 to 31%, and no year with ROIC below 21%, even through COVID.
That record is what makes the valuation call harder to dismiss, but it does not make it airtight. The company has also been buying smaller competitors in a fragmented industry with more than 34,000 U.S. operators, completing 30 to 45 bolt-on acquisitions a year, which helps explain why the business can keep expanding without needing the same capital demands as heavier industries. Still, the framework did not spell out the exact revenue growth or margin assumptions that produced the $19.63 figure, and that is the weak point in the case.
Even so, the math behind the call is blunt enough. If the fair value estimate is $19.63 and the stock is at $47.77, the market price sits about $28.14 above the estimate, or roughly 143% higher. That does not prove the shares must fall, but it does show that the current price already assumes a lot more than the valuation model does. The unanswered question is whether Rollins can keep compounding fast enough to close that gap before the market does it for investors.
